Czech out this Bohemian beauty
Your local paper, whenever you want it.
Eagle Bay Brewing Co
Czech, please.
Eagle Bay Brewing Co has delved back to the origins of pale lager with its latest release, Fresh Hop Bohemian Pilsner.
Pilsner takes its name from the Bohemian city of Plzen (or Pilsen in German) where the world's first pale lager was brewed in 1842.
The South West brewers have sourced floor malted Bohemian Pilsner malt directly from the Czech Republic alongside aromatic Summer Saaz and Victoria hops from Margaret River Hops, delivered to the brewery as whole cones just hours after being picked.
Eagle Bay describes its Bohemian Pilsner as a fresh hop beer with uniquely modern retro twist where 'old world meets new world'.
The result is a bready, biscuity malt flavour followed by apricot, herbal and citrus characters from the local hops.
Czech, or Bohemian-style, pilsners are traditionally crisp like other pilsner-style beers but have a spicy hop character and a nice, rich, complex maltiness. Bohemian-style pilsners usually have a bit more malt sweetness than German-style pils, which helps counter the hop bitterness, making it a more balanced, well-rounded beer.
As you would expect, Fresh Hop Bohemian Pilsner pours a very pale gold you can see straight through.
There's a very light head on it, and those fruity and herbal flavours are immediately evident on the nose.
But from the very first sip, you know you are drinking a proper pils, with that hop bitterness coming to the fore ahead of those malt flavours.
It's a fresh take on a classic.
With a 4.5 per cent ABV, it's very sessionable but also ideal for sharing with like-minded Boho spirits.
$6.99 for a single or $82 for a 16-pack cube
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
10 hours ago
- Sydney Morning Herald
Melbourne's key street has got its buzz back, and it's bigger than, well ...
A slow decay crept along the shopping strip, with the Walk Arcade closing in 2020 and David Jones closing its menswear store in 2022. The rise of online shopping took customers out of stores and retail vacancies peaked at 27.9 per cent when the city shut down during the coronavirus pandemic. Chris Langford, the former Hawthorn champion turned property developer at Newmark Capital, remembers standing on the roof of what was to become the Mecca flagship at a site inspection before signing the deal to buy the property for $121 million in July 2020. 'There was no one in the Bourke Street Mall,' he says. 'It took a bit of conviction at that point to say: is Melbourne going to bounce back? Will Bourke Street ever be as good as it was?' As a kid growing up in country Victoria, coming down to Melbourne to visit the shops and see the sights was once a major day out. Loading It was an exciting destination, a place where you felt like you were in the thick of things; where there was always something new to be discovered. Gradually that feeling is returning. Bourke Street's revival at the top end of the city started with Chris Lucas' Maison Batard restaurant opening late last year. The venue spans four levels – a red velvet bar in the basement, a Parisian-style bistro with an oyster bar on the ground floor, a clubby private dining room on the first floor and a rooftop terrace. Across the road is luxury hotel Le Meridien Melbourne, which hotel giant Marriott Bonvoy opened in the former Palace Theatre building, while the O'Brien Group is preparing to open Juliet's Terrace in the former Job Warehouse Building at 58 Bourke Street. The newcomers join hospitality stalwarts like Pellegrini's and Grossi Florentino, which have operated for 71 and 97 years respectively, and the long-standing Hill of Content bookstore which survived the sale of its building by moving 120 metres up the street. It is the combination of major players and tiny independents that enables Bourke Street to offer something different to the suburban mega-malls. Inspiration can be found from E.W. Cole, who operated what was once the world's largest book store, The Cole's Book Arcade, on the site which is now Mecca's store. The arcade featured an instore aviary, a symphony orchestra and monkey exhibit and attracted literary luminaries including Mark Twain and Rudyard Kipling. Cole encouraged customers to spend as much time as they wanted in the store with the mantra: 'No one has to buy, you can read what you like.' Loading His philosophy could be the key to Bourke Street's reinvention. 'It's pretty extraordinary that something from the late 1800s could actually be the centre of the dartboard that we were trying to hit 200 years later,' says Mecca founder Jo Horgan. 'He was a maestro of the customer experience and people flocked from around the world.' In a world where everything is available online, a trip to Bourke Street is once again offering an experience you can't get everywhere else.
The Age
10 hours ago
- The Age
Melbourne's key street has got its buzz back, and it's bigger than, well...
A slow decay crept along the shopping strip, with the Walk Arcade closing in 2020 and David Jones closing its menswear store in 2022. The rise of online shopping took customers out of stores and retail vacancies peaked at 27.9 per cent when the city shut down during the coronavirus pandemic. Chris Langford, the former Hawthorn champion turned property developer at Newmark Capital, remembers standing on the roof of what was to become the Mecca flagship at a site inspection before signing the deal to buy the property for $121 million in July 2020. 'There was no one in the Bourke Street Mall,' he says. 'It took a bit of conviction at that point to say: is Melbourne going to bounce back? Will Bourke Street ever be as good as it was?' As a kid growing up in country Victoria, coming down to Melbourne to visit the shops and see the sights was once a major day out. Loading It was an exciting destination, a place where you felt like you were in the thick of things; where there was always something new to be discovered. Gradually that feeling is returning. Bourke Street's revival at the top end of the city started with Chris Lucas' Maison Batard restaurant opening late last year. The venue spans four levels – a red velvet bar in the basement, a Parisian-style bistro with an oyster bar on the ground floor, a clubby private dining room on the first floor and a rooftop terrace. Across the road is luxury hotel Le Meridien Melbourne, which hotel giant Marriott Bonvoy opened in the former Palace Theatre building, while the O'Brien Group is preparing to open Juliet's Terrace in the former Job Warehouse Building at 58 Bourke Street. The newcomers join hospitality stalwarts like Pellegrini's and Grossi Florentino, which have operated for 71 and 97 years respectively, and the long-standing Hill of Content bookstore which survived the sale of its building by moving 120 metres up the street. It is the combination of major players and tiny independents that enables Bourke Street to offer something different to the suburban mega-malls. Inspiration can be found from E.W. Cole, who operated what was once the world's largest book store, The Cole's Book Arcade, on the site which is now Mecca's store. The arcade featured an instore aviary, a symphony orchestra and monkey exhibit and attracted literary luminaries including Mark Twain and Rudyard Kipling. Cole encouraged customers to spend as much time as they wanted in the store with the mantra: 'No one has to buy, you can read what you like.' Loading His philosophy could be the key to Bourke Street's reinvention. 'It's pretty extraordinary that something from the late 1800s could actually be the centre of the dartboard that we were trying to hit 200 years later,' says Mecca founder Jo Horgan. 'He was a maestro of the customer experience and people flocked from around the world.' In a world where everything is available online, a trip to Bourke Street is once again offering an experience you can't get everywhere else.
News.com.au
a day ago
- News.com.au
Precision Points: When it comes to biotechs' messaging, a lingering KISS goes a long way
In Precision Points, Precision Funds Management executive directors Dermot Woods and Andy Clayton draw on insights from two decades on the front lines of equity markets to share their expertise with Stockhead readers. Today, Dermot Woods outlines the Perth based fund's approach to investing in the biotech space, which has parallels with its more familiar ground of the resources sector. As with its more familiar bailiwick of resources, the Precision Funds Management deploys the KISS acronym when investing in the biotech sector. Keep It Simple Stupid. 'The information has to be presented simply enough so that we semi understand it,' Precision executive director Dermot Woods says. 'It helps if can pronounce the name of a disease, or it has an action we can remember.' Woods deploys plenty of rock-kicking analogies to describe the entity's nascent interest in the biotech sector. For a start, the risk and reward parameters are strikingly similar. As with each new 'Olympic Dam-style' copper play, the chances are that the latest in-vogue drug program won't be the next Neuren Pharmaceuticals (ASX:NEU). (Neuren and its partner Acadia famously commercialised the Rett syndrome drug Daybue and the achievement is a rare exemplar of ultimate achievement). But who says investors can't have fun along the way? Have a crack Along the convoluted drug development path, it's a case of getting that risk-reward equation down pat. 'Investing in West African gold stocks is risky, but everyone knows they are risky, so the risk is priced in,' Woods says. In contrast, the biotech sector is still emerging from its post-pandemic nuclear winter that descended in late 2022. Despite notable capital raisings such as Clarity Pharmaceuticals' (ASX:CU6) $200 million whip-'round, local biotechs still are starved of capital. The upside? There's plenty of 'mispriced risk' and now is the time to 'have a crack'. More than a punt As with an iron ore explorer that chanced on lithium, Precision tentatively embraced biotech for the wrong reason. 'Like most fund managers, we had a 'zero biotech' rule for about 20 years,' he says. 'We then thought the aggregation of big data would mean that drug discoveries became quicker. 'It hasn't happened yet – but it will.' (Big data aggregation refers to collecting, combining, and summarising large labs of data into more manageable and useful formats). In the mining sector, Precision likes to see a certified resource, 'rather than punting on a piece of ground'. Precision's life sciences ethos is similar: avoid the whimsical preclinical and phase I stuff in favour of the mid-to-late pointy end. If that means writing a bigger cheque, then so be it. To date, Precision has weighed in on four ASX drug developers. The biggest, Dimerix (ASX:DXB), accounts for 4% of the fund's circa $100 million of assets. Stroke drug developer Argenica Therapeutics (ASX:AGN) comprises around 1%. Dimerix goes from 'really cheap to cheap' Precision's centrepiece biotech exposure is Dimerix, which is in phase III with its drug candidate for the kidney disease focal segmental glomerulosclerosis. The fund initially took part in the company's $20 million placement in March 2024 at 30 cents a share, after its successful interim readout. After that, Dimerix inked four global partnership deals that raked in $65 million, with up to $1.4 billion in potential milestones. Woods says Dimerix's funding position substantially derisks the company. Dimerix won't need money until the 'moment of truth': the outcome of the phase III study. Woods admits the fund could have got in cheaper, with Dimerix stock trading at a paltry six cents two years ago. He says it's a case of a stock going from 'really cheap' to cheap – with significantly less risk. Argenica was a stroke of luck The Perth-based Argenica is testing its stroke drug candidate in a local phase II trial. Having enrolled 92 patients across eight hospitals, investors should expect a data readout in early September. Ultimately, Argenica eyes a phase III trial, but the US Food & Drug Administration has asked for more safety data before it can approve the study. Given the company needs to wait for its phase II trial anyway, time is on its side. Woods says the fund weighed into Argenica three years ago, at about 40% below current levels. He says the fund was drawn to Argenica partly because of CEO Dr Liz Dallimore's 'clear vision' on the company's strategy. 'If this trial , we can buy a decent return for a very decent price," Woods says. Not PYC-ing out on a punt Despite being mining focused, Perth-based drug maker PYC Therapeutics (ASX:PYC) once was Precision's biggest holding, before the fund flipped the stock at a profit. By combining existing ribonucleic acid (RNA) drug design with its proprietary delivery platform, PYC is developing precision therapies for patients with genetic diseases that have no treatment options. PYC's lead program covers the rare eye disease retinitis pigmentosa. It is also targeting autosomal dominant optic atrophy, Phelan-McDermid syndrome and autosomal dominant polycystic kidney disease. The company's once-muddled story is gaining traction, with the stock more than doubling over the last years and pushing its market valuation over $700 million. 'They have done a really good job,' Woods says. 'But for us it's probably a bit too early stage.' Precision also took a profitable punt on a fourth non-WA drug developer, which Woods declines to name. KISS and take up Woods' overriding message to biotech management is to go for the big KISS – and enjoy the investor passion. He says KISS is especially relevant when presenting to fund managers who might look at thousands of stocks. Beyond the dense Powerpoints, Precision seeks an unequivocal answer to a precise question. It's not number 42 and the meaning of the universe, but 'are they asking for more money?'
